Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  HIV Healthy, HIV-uninfected male and female participants Prior RV306 recipients who were randomized to receive active vaccine with late boosting at month 12, 15, or 18 and who completed all vaccinations Have a Thai identity card Must be at low risk for HIV infection per investigator assessment Must be able to understand and complete the informed consent process Must be capable of reading Thai Must successfully complete a Test of Understanding prior to enrollment Must be in good general health without clinically significant medical history HIV-uninfected per diagnostic algorithm within 45 days of enrollment Laboratory screening analysis: 1. Hemoglobin: Women ≥11.0 g/dL, Men ≥11.5 g/dL 2. White cell count: 4,000 to 11,000 cells/mm3 3. Platelets: 150,000 to 450,000/mm3 4. ALT and AST ≤1.25 institutional upper limit of reference range 5. Creatinine: ≤1.25 institutional upper limit of reference range 6. Urinalysis (dipstick) for blood and protein no greater than 1+ and negative glucose  Asplenia: any condition resulting in the absence of a functional spleen Bleeding disorder diagnosed by a medical doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) Women breast-feeding or pregnant (positive pregnancy test) or planning to become pregnant during the window between study enrollment and 3 months after the vaccination visit History of anaphylaxis or other serious adverse reaction to vaccines Volunteer has received any of the following substances: 1. Chronic use of therapies that may modify immune response, such as IV immune globulin and systemic corticosteroids (in doses of > 20 mg/day prednisone equivalent for periods exceeding 10 days) Note: The following exceptions are permitted and will not study participation: use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on investigator clinical judgment) at least 2 weeks prior to enrollment in this study 2. Blood products within 120 days prior to HIV screening 3. Immunoglobulins within 30 days prior to HIV screening 4. Any licensed vaccine within 14 days prior to initial study vaccine administration in the present study 5. Receipt of any investigational HIV vaccine other than RV306 products 6. Investigational research agents or vaccine within 30 days prior to enrollment in the present study 7. Anti-tuberculosis prophylaxis or therapy during the past 90 days prior to enrollment Active sexually transmitted infection confirmed by clinical exam and diagnostic test Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contradiction to protocol compliance or impairs a volunteer's ability to give informed consent Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within 5 years prior to enrollment, a history of suicide ideation or attempt Study site employees who are involved in the protocol and/or may have direct access to study related area Final evaluation of will be based on the medical judgment of the investigator based on his/her medical and research experience